Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL441490 | 0.82 | GBA1 (0.38) | MEN1KMT2ATP53SMN1; SMN2USP2 | |
| SCHEMBL8071370 | 0.82 | PAOX (0.39) | CACNA2D1TP53SMN1; SMN2USP2ALDH1A1 | |
| SCHEMBL9276057 | 0.80 | CACNA2D1 (0.43) | MEN1KMT2ACACNA2D1TP53SMN1; SMN2 | |
| SCHEMBL22790763 | 0.80 | CACNA2D1 (0.47) | MEN1KMT2ACACNA2D1SMN1; SMN2HRH3 | |
| SCHEMBL26352150 | 0.78 | HRH3 (0.48) | MEN1KMT2ACACNA2D1SMN1; SMN2HRH3 | |
| SCHEMBL16349983 | 0.78 | KMT2A (0.37) | MEN1KMT2ARAB9ANPC1ALDH1A1 | |
| SCHEMBL19322329 | 0.77 | USP2 (0.36) | MEN1KMT2ATP53SMN1; SMN2USP2 | |
| SCHEMBL28633359 | 0.77 | PAOX (0.42) | CACNA2D1TP53SMN1; SMN2USP2ALDH1A1 | |
| SCHEMBL13600648 | 0.77 | MEN1 (0.36) | MEN1KMT2ATP53SMN1; SMN2USP2 | |
| SCHEMBL19068697 | 0.76 | USP2 (0.35) | MEN1KMT2AUSP2RAB9ASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230301984-A1 | CYCLIC COMPOUNDS FOR USE IN TREATING RETINAL DEGENERATION | THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230301984-A1 | CYCLIC COMPOUNDS FOR USE IN TREATING RETINAL DEGENERATION | THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230301984-A1 | CYCLIC COMPOUNDS FOR USE IN TREATING RETINAL DEGENERATION | ALDH1A2, PDE6D, PDE6C | MEN1 4843/4885KMT2A 1905/4885CACNA2D1 2469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.